Follow us

Leading international law firm Herbert Smith Freehills has advised China International Capital Corporation and Citigroup as joint sponsors of Jenscare Scientific Co., Ltd. (09877.HK)'s listing on the Main Board of the Hong Kong Stock Exchange.

Jenscare is a China-based medical device company dedicated to the development of interventional products for the treatment of structural heart diseases. The company has developed a series of treatment solutions targeting different types of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases and heart failure. Jenscare listed on 10 October 2022.

"We congratulate Jenscare, one of the leading medical device manufacturers, on beginning its new chapter by listing on the Hong Kong Stock Exchange," said Hong Kong partner Matt Emsley. "We are delighted to have worked with the company and the joint sponsors on this IPO and wish their continued success."

Herbert Smith Freehills leads the legal market in advising sponsors and underwriters on Hong Kong IPOs, with 12 IPOs successfully listed on the Hong Kong Stock Exchange in the past 12 months.

"We have maintained a robust record of advising Chinese companies seeking listings despite volatile market conditions," said Herbert Smith Freehills Kewei joint operation partner Stanley Xie. "With proven expertise in advising on high-profile capital markets transactions, we look forward to continuing our support to clients on their fundraising activities."

Herbert Smith Freehills has advised on over a dozen of healthcare and biotech listings since the Hong Kong Stock Exchange introduced its new regime for biotech listings in 2018.

"Our China-dedicated capital markets team, located across offices in Hong Kong and Mainland China, collaborated closely to provide quality legal services to our clients," said Hong Kong senior registered foreign lawyer Jin Kong. "Our team keeps abreast of market trends, ready to support clients from different sectors in their pursuit of capital." 

Partners Matt, Stanley and Jin jointly led the team advising the joint sponsors, assisted by Maisie Ko (senior associate), Crystal Chan (associate), Haiyun Chen (registered foreign lawyer), Reagan Li (associate) and Jessica Lu (legal assistant) in Hong Kong, and Agatha Shen (counsel), Sean Ji (associate), Ting Wang (associate) and Han Ye (legal assistant) from Kewei. Jaime Fong (senior associate), Gigi Lo (associate), Angela Yuen (associate) and Camille Chai (trainee solicitor) in Hong Kong also provided support on this deal.

Legal manager Marine Jin led Herbert Smith Freehills Kewei Joint Operation’s Alternative Legal Services business to provide high-efficiency solutions for verification and other document-intensive processes during the listing, assisted by Shawna Peng (senior legal analyst) and Chloe Hu (legal analyst).



史密夫斐尔香港办公室合伙人艾迈修(Matt Emsley)表示:“健世科技是领先的医疗器械制造商之一,祝贺公司在联交所上市,开启新的篇章。我们非常荣幸在这次IPO中与健世科技和保荐人合作,衷心祝愿他们不断取得成功。”


科伟史密夫斐尔联营办公室合伙人谢守德(Stanley Xie)表示:“尽管市场状况不稳定,我们在为寻求上市的中国公司提供咨询方面一直保持着优秀记录。凭借在为备受瞩目的资本市场交易提供法律咨询方面的过硬实力,我们期待继续为客户就融资活动提供支持。”


史密夫斐尔香港办公室合伙人(高级注册外国律师)孔瑾(Jin Kong)表示:“我们专注于中国的资本市场团队遍及中国内地和香港办公室。团队密切合作,致力于为客户提供优质的法律服务。我们紧跟市场趋势,随时准备为来自各个行业的客户寻求资本提供支持。”

合伙人艾迈修、谢守德和孔瑾率领律师团队为此次上市的联席保荐人提供法律服务。主要团队成员包括香港办公室高美诗(Senior Associate)、陈念彤(Associate)、陈海韵(Registered Foreign Lawyer)、李晓剑(Associate)和卢嘉铮(Legal Assistant),上海办公室沈雪琦(Counsel)、季晓源(Associate)、王婷(Associate)和叶晗(Legal Assistant)。香港办公室方靖颐 (Senior Associate)、卢淑妍(Associate)、 阮颖欣(Associate)和查紫婷(Trainee Solicitor)也为该笔交易提供了支持。

金燊(Legal Manager)率领的科伟史密夫斐尔联营办公室替代性法律服务(ALT)联合团队在上市项目期间为招股书验证及其他文件密集型工作提供高效率的解决方案。彭祺程 (Senior Legal Analyst)和胡彦珽 (Legal Analyst) 提供支持。

Key contacts

Matthew Emsley photo

Matthew Emsley

Managing Partner, China, Hong Kong

Matthew Emsley
Stanley Xie photo

Stanley Xie

, Hong Kong

Stanley Xie
Jin Kong photo

Jin Kong

Senior Foreign Registered Lawyer (USA – New York), Hong Kong

Jin Kong

Media contact

For further information on this article please contact

Sally Greig

Head of Communications, Asia

Hong Kong

Media contact

For further information on this article please contact

Vivian Huang

Communications Manager, China


Mainland China Hong Kong Corporate Capital Markets Equity Capital Markets Pharmaceuticals and Healthcare Healthcare Matthew Emsley Stanley Xie Jin Kong